274 reports of this reaction
2.1% of all CEFUROXIME AXETIL reports
#4 most reported adverse reaction
DYSPNOEA is the #4 most commonly reported adverse reaction for CEFUROXIME AXETIL, manufactured by American Health Packaging. There are 274 FDA adverse event reports linking CEFUROXIME AXETIL to DYSPNOEA. This represents approximately 2.1% of all 13,186 adverse event reports for this drug.
Patients taking CEFUROXIME AXETIL who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for CEFUROXIME AXETIL, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for CEFUROXIME AXETIL:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 274 FDA reports for CEFUROXIME AXETIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.1% of all adverse event reports for CEFUROXIME AXETIL, making it a notable side effect.
If you experience dyspnoea while taking CEFUROXIME AXETIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.